Roche touts full da­ta for drug in first-line PIK3CA-mu­tat­ed breast can­cer

Roche’s breast can­cer com­bi­na­tion of in­avolis­ib plus pal­bo­ci­clib and ful­ves­trant showed off new da­ta Fri­day, with the com­pa­ny tout­ing a 57% re­duc­tion in the risk of dis­ease pro­gres­sion or death in pa­tients with PIK3CA-mu­tat­ed HR-pos­i­tive HER2-neg­a­tive breast can­cer.

The Big Phar­ma is hop­ing in­avolis­ib is the first ap­proval for a first-line treat­ment in the dis­ease, which would pit it against No­var­tis’ Piqray, ap­proved in the sec­ond-line set­ting.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER